Wealth Enhancement Trust Services’s MoonLake Immunotherapeutics MLTX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$954	Buy	+49	New	+$888	﹤0.01%	1140

Other funds holding MLTX

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Trust Services's MLTX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 49 shares worth $954. The stake represents ﹤0.01% of the portfolio and ranks #1140 among its holdings.

73 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Wealth Enhancement Trust Services held 49 shares of MoonLake Immunotherapeutics worth $954 as of Q2 2026.
MoonLake Immunotherapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1140 holding.
73 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.